SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2019 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 40.3% | -206.1% | |
| Return on assets | – | – | -181.9% | |
| Current ratio | – | – | 9.87 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | 8.7× | – | |
| Capex to revenue | – | 0.3% | – | |
| Diluted shares | 12M | 17M | 748M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Summit Therapeutics generated $655.97M from operations and spent $1.85M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$655.97M
Used
$1.85M
Capital expenditure$1.85M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-11174.8%
×Asset turnover0.00×
×Equity multiplier3.70×
=Return on equity, FY2022-75.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -11174.8% | 0.00× | 3.70× | -75.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.08B
- Cash generatingOperating cash flow above zero-$322.93M
- Return on assets improvedROA up on the prior year-109.0% → -247.9%
- Earnings backed by cashOperating cash flow above net income-$322.93M vs -$1.08B
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose10.15 → 9.87
- No dilutionShare count did not rise719M → 748M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → –